Tumor Cell-Derived Extracellular Vesicle-Coated Nanocarriers: An Efficient Theranostic Platform for the Cancer-Specific Delivery of Anti-miR-21 and Imaging Agents

• Published in: ACS nano Vol. 12; no. 11; pp. 10817 - 10832
• Main Authors: JC Bose, Rajendran, Uday Kumar, Sukumar, Zeng, Yitian, Afjei, Rayhaneh, Robinson, Elise, Lau, Kenneth, Bermudez, Abel, Habte, Frezghi, Pitteri, Sharon J., Sinclair, Robert, Willmann, Juergen K, Massoud, Tarik F., Gambhir, Sanjiv S., Paulmurugan, Ramasamy
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 27-11-2018
• Subjects: Animals; Antibiotics, Antineoplastic - administration & dosage; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - metabolism; Breast Neoplasms - therapy; Doxorubicin - administration & dosage; Drug Carriers - chemistry; Extracellular Vesicles - chemistry; HEK293 Cells; Humans; Magnetic Resonance Imaging; Mice; MicroRNAs - antagonists & inhibitors; MicroRNAs - chemistry; Molecular Imaging; Nanoparticles - chemistry; Phototherapy; Theranostic Nanomedicine; extracellular vesicles; MR imaging; miRNA therapeutics; luciferase; breast cancer; cancer nanotheranostics; molecular imaging
• ISSN: 1936-0851; 1936-086X
• DOI: 10.1021/acsnano.8b02587

MicroRNAs are critical regulators of cancer initiation, progression, and dissemination. Extensive evidence suggests that the inhibition of over-expressed oncogenic miRNA function can be a robust strategy for anticancer therapy. However, in vivo targeted delivery of miRNA therapeutics to various types of cancers remains a major challenge. Inspired by their natural synthesis and cargo delivery capabilities, researchers have exploited tumor cell-derived extracellular vesicles (TEVs) for the cancer-targeted delivery of therapeutics and theranostics. Here, we investigate a TEV-based nanoplatform for multimodal miRNA delivery and phototherapy treatments as well as the magnetic resonance imaging of cancer. We demonstrated loading of anti-miR-21 that blocks the function of endogenous oncogenic miR-21 over-expressed in cancer cells into and subsequent delivery by TEVs derived from 4T1 cells. We also produced Cy5-anti-miR-21-loaded TEVs from two other cancer cell lines (HepG2 and SKBR3) and confirmed their robust homologous and heterologous transfection efficiency and intracellular Cy5-anti-miR-21 delivery. Additionally, TEV-mediated anti-miR-21 delivery attenuated doxorubicin (DOX) resistance in breast cancer cells with a 3-fold higher cell kill efficiency than in cells treated with DOX alone. We then investigated TEVs as a biomimetic source for the functionalization of gold–iron oxide nanoparticles (GIONs) and demonstrated nanotheranostic properties of TEV-GIONs in vitro. TEV-GIONs demonstrated excellent T2 contrast in in vitro magnetic resonance (MR) imaging and resulted in efficient photothermal effect in 4T1 cells. We also evaluated the biodistribution and theranostic property of anti-miR-21 loaded TEV-GIONs in vivo by labeling with indocyanine green near-infrared dye. We further validated the tumor specific accumulation of TEV-GIONs using MR imaging. Our findings demonstrate that the distribution pattern of the TEV-anti-miR-21-GIONs correlated well with the tumor-targeting capability as well as the activity and efficacy obtained in response to doxorubicin combination treatments. TEVs and TEV-GIONs are promising nanotheranostics for future applications in cancer molecular imaging and therapy.